소아용 백신 시장 : 기회, 성장 촉진요인, 산업 동향 분석과 예측(2024-2032년)

Pediatric Vaccines Market size is expected to record an 8.9% CAGR between 2024 and 2032, driven by increasing partnerships and investments.

Of late, organizations are collaborating to bolster R and D activities to produce more effective and accessible vaccines for children. These investments are paving the way for new vaccine formulations and technologies, enhancing protection against a range of diseases. This steadfast commitment to investment and collaboration ensures that vaccines evolve in tandem with health challenges for ultimately promoting better health outcomes for children globally. For example, in September 2023, GSK and Save the Children extended their partnership for another five years. GSK is channeling £15 million to elevate vaccination rates, with a particular focus on 'zero dose' children in Ethiopia and Nigeria.

The pediatric vaccines industry is segmented based on type, technology, indication, end-use, and region.

The market share from the monovalent vaccines type segment is expected to witness substantial growth through 2032, due to the rising preference for targeting individual pathogens or their specific strains. Monovalent vaccines focus on diseases within pediatric populations by concentrating on a singular virus or bacterium. These vaccines are undergoing stringent clinical trials to bolster their efficacy and safety. As a result, ongoing advancements are fine-tuning monovalent vaccines, making them not only more effective but also easier to administer, thereby amplifying disease prevention in pediatric care.

In terms of end-use, the pediatric vaccines market value from the private segment is slated to generate notable revenue during 2024-2032 driven by the growing emphasis on timely and effective immunizations for children. Healthcare facilities are ramping up their vaccination services to ensure thorough immunization for their young patients. Private clinics are diversifying their offerings, providing a broad spectrum of pediatric vaccines to meet various health needs and prevent diseases. Furthermore, innovations in vaccine technology and delivery methods are boosting the effectiveness and ease of pediatric vaccines in private practices.

Europe pediatric vaccines industry size is likely to record a significant growth rate through 2032 led by global health initiatives. Several countries are joining forces on programs aimed at bolstering child health through comprehensive vaccination strategies. With global health organizations intensifying their efforts to amplify vaccine coverage, European healthcare providers are responding by enhancing their private vaccination services. This ongoing collaboration is set to elevate vaccination rates and improve health outcomes for children throughout Europe.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of chronic and infectious disease in children
    • 3.2.1.2 Increasing birth rate
    • 3.2.1.3 Growing research and development activities for vaccine development
    • 3.2.1.4 Rising government initiatives and funding
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulations for the approval of vaccines in developed nations
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Million)

• 5.1 Key trends
• 5.2 Monovalent vaccines
• 5.3 Multivalent vaccines

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Million)

• 6.1 Key trends
• 6.2 Live attenuated vaccines
• 6.3 Inactivated vaccines
• 6.4 Toxoid vaccines
• 6.5 Conjugate vaccines
• 6.6 Other technologies

Chapter 7 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Million)

• 7.1 Key trends
• 7.2 Influenza
• 7.3 Human papilloma virus
• 7.4 Measles, mumps, and rubella
• 7.5 Polio
• 7.6 Pneumococcal disease
• 7.7 Diphtheria, pertussis, and tetanus
• 7.8 Other indications

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Million)

• 8.1 Key trends
• 8.2 Public
• 8.3 Private

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Astellas Pharma, Inc.
• 10.2 AstraZeneca Plc
• 10.3 CSL Limited
• 10.4 Daiichi Sankyo Company Limited
• 10.5 Emergent BioSolutions, Inc,
• 10.6 GlaxoSmithKline Plc
• 10.7 Grifol SA
• 10.8 Meissa Vaccines, Inc.
• 10.9 Merck and Co. Inc.
• 10.10 Panacea Biotec
• 10.11 Pfizer, Inc.
• 10.12 Sanofi SA
• 10.13 Serum Institute of India
• 10.14 Takeda Pharmaceutical Industries Limited